Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Kaname, Yamashita"'
Autor:
Hiroshi Kotani, Tomoyoshi Yamano, Justin C. Boucher, Shigeki Sato, Hiroyuki Sakaguchi, Koji Fukuda, Akihiro Nishiyama, Kaname Yamashita, Koushiro Ohtsubo, Shinji Takeuchi, Takumi Nishiuchi, Hiroko Oshima, Masanobu Oshima, Marco L. Davila, Seiji Yano
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-6 (2024)
Abstract Precision medicine has drastically changed cancer treatment strategies including KRAS-mutant cancers which have been undruggable for decades. While intrinsic or acquired treatment resistance remains unresolved in many cases, epigenome-target
Externí odkaz:
https://doaj.org/article/b9b2e0380ce9438081e69ef411f40371
Autor:
Hiroshi Kotani, Hiroko Oshima, Justin C. Boucher, Tomoyoshi Yamano, Hiroyuki Sakaguchi, Shigeki Sato, Koji Fukuda, Akihiro Nishiyama, Kaname Yamashita, Koushiro Ohtsubo, Shinji Takeuchi, Takumi Nishiuchi, Masanobu Oshima, Marco L. Davila, Seiji Yano
Publikováno v:
Journal of Biomedical Science, Vol 31, Iss 1, Pp 1-13 (2024)
Abstract Background KRAS mutations frequently occur in cancers, particularly pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer. Although KRAS G12C inhibitors have recently been approved, effective precision therapies
Externí odkaz:
https://doaj.org/article/e76a3f8454924a68ab32ec86f27f0f26
Autor:
Akihiro Nishiyama, Shigeki Sato, Hiroyuki Sakaguchi, Hiroshi Kotani, Kaname Yamashita, Koushiro Ohtsubo, Shigeki Nanjo, Seiji Yano, Keishi Mizuguchi, Hiroko Ikeda, Shinji Takeuchi
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
We report a case of limited effectiveness of dabrafenib and trametinib in a 59-year-old man with poorly differentiated lung carcinoma and a rare BRAF K601E mutation. The patient, unresponsive to chemotherapy and immunotherapy, received these targeted
Externí odkaz:
https://doaj.org/article/67c78e62172b42b580e93f5cade774a9
Autor:
Akihiro Nishiyama, Shigeki Sato, Hiroyuki Sakaguchi, Hiroshi Kotani, Kaname Yamashita, Koushiro Ohtsubo, Keishi Mizuguchi, Hiroko Ikeda, Kenji Iino, Hirofumi Takemura, Shinji Takeuchi
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
In the realm of rare cardiac tumors, intimal sarcoma presents a formidable challenge, often requiring innovative treatment approaches. This case report presents a unique instance of primary intimal sarcoma in the left atrium, underscoring the critica
Externí odkaz:
https://doaj.org/article/5b28db188c8a4b39872e162ed79f8cf7
Autor:
Rong Wang, Tadaaki Yamada, Kenji Kita, Hirokazu Taniguchi, Sachiko Arai, Koji Fukuda, Minoru Terashima, Akihiko Ishimura, Akihiro Nishiyama, Azusa Tanimoto, Shinji Takeuchi, Koshiro Ohtsubo, Kaname Yamashita, Tomoyoshi Yamano, Akihiro Yoshimura, Koichi Takayama, Kyoichi Kaira, Yoshihiko Taniguchi, Shinji Atagi, Hisanori Uehara, Rikinari Hanayama, Isao Matsumoto, Xujun Han, Kunio Matsumoto, Wei Wang, Takeshi Suzuki, Seiji Yano
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
Cancer cells develop resistance to tyrosine kinase inhibitors targeting EGFR. Here, the authors explore the mechanism of resistance to one such inhibitor - osimertinib - and find that resistance is caused by increased expression and activation of the
Externí odkaz:
https://doaj.org/article/286176aadbbc411dbfd32550becc33c5
Autor:
Yuta Adachi, Naohiro Yanagimura, Chiaki Suzuki, Sakiko Ootani, Azusa Tanimoto, Akihiro Nishiyama, Kaname Yamashita, Koushiro Ohtsubo, Shinji Takeuchi, Seiji Yano
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-4 (2020)
Abstract Background A BRAF V600E mutation is found as driver oncogene in patients with non-small cell lung cancer. Although combined treatment with dabrafenib and trametinib is highly effective, the efficacy of reduced doses of the drugs in combinati
Externí odkaz:
https://doaj.org/article/248ccedf4c7e4010a00b7c2f3c8a2c40
Autor:
Azusa Tanimoto, Shinji Takeuchi, Hiroshi Kotani, Kaname Yamashita, Tadaaki Yamada, Koushiro Ohtsubo, Hiromichi Ebi, Hiroko Ikeda, Seiji Yano
Publikováno v:
BMC Pulmonary Medicine, Vol 18, Iss 1, Pp 1-4 (2018)
Abstract Background Pulmonary carcinosarcoma (PCS) is a rare primary lung malignancy and has a poor prognosis among lung tumor histological subtypes. However, an appropriate treatment strategy has not been developed for unresectable PCS. Case present
Externí odkaz:
https://doaj.org/article/7a69227862094f0caf65786b14b15e03
Autor:
Hiroshi, Yaegashi, Takahiro, Nohara, Kazuyoshi, Shigehara, Kouji, Izumi, Yoshifumi, Kadono, Tomoyuki, Makino, Kaname, Yamashita, Koushiro, Ohtsubo, Hiroko, Ikeda, Atsushi, Mizokami
Publikováno v:
Cancer Diagn Progn
Background/Aim: Primary mediastinal non-seminomatous germ cell tumors (PMNSGCTs) are occasionally complicated by a hematologic malignancy, as with somatic-type malignant tumors called germ cell tumors with somatic-type malignancy (GCTSTM) and are kno
Autor:
Koushiro, Ohtsubo, Kunio, Miyake, Sachiko, Arai, Koji, Fukuda, Chiaki, Suzuki, Hiroshi, Kotani, Azusa, Tanimoto, Akihiro, Nishiyama, Shigeki, Nanjo, Kaname, Yamashita, Shinji, Takeuchi, Seiji, Yano
Publikováno v:
Cancer Diagn Progn
Background/Aim: We previously reported the usefulness of aberrant methylation of tumor suppressive miRNAs in bile to discriminate pancreaticobiliary cancers (PBCs) from benign pancreaticobiliary diseases (BD). Here we performed a methylation analysis
Autor:
Seiji Yano, Shu Taira, Eishu Hirata, Naoyoshi Onoda, Junji Matsui, Koshiro Ohtsubo, Kaname Yamashita, Shinji Takeuchi, Akihiro Nishiyama, Azusa Tanimoto, Hirokazu Taniguchi, Koji Fukuda, Sachiko Arai, Tadaaki Yamada, Rong Wang
Supplementary Table 3 shows the effects of lenvatinib and sorafenib on the production of angiogenesis-related cytokines from ATC cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58bcd7b9f2bb50eb09b1756c94558c04
https://doi.org/10.1158/1535-7163.22509372.v1
https://doi.org/10.1158/1535-7163.22509372.v1